CRP and coronary artery disorder: In contrast, Ridker et al. tested low-dose methotrexate, a purine metabolism inhibitor, in individuals with a history of AMI or multivessel CAD who also had diabetes or metabolic syndrome and failed to demonstrate a beneficial effect on cardiac events or a reduction in CRP, IL-6, and IL-1b levels over two years [29].